Robust H1 2025 Performance
Lonza delivered CHF 3.6 billion in sales across the group, translating into 19% CER sales growth compared to 2024. The core EBITDA was CHF 1.1 billion, representing margin growth of 0.4 percentage points to 29.6%.
CDMO Business Growth
The core CDMO business, excluding CHI, saw 23.1% sales growth leading to a core EBITDA margin slightly above 30%. The CDMO outlook for full year 2025 was upgraded to 20% to 21% CER sales growth and a core EBITDA margin of 30% to 31%.
Integrated Biologics Surge
Integrated Biologics reported almost 40% CER sales growth compared to H1 2024, supported by the Vacaville acquisition and sustained high demand, resulting in a core EBITDA margin of 36%.
Advanced Synthesis Performance
Advanced synthesis reported above 18% CER sales growth compared to H1 2024 with a core EBITDA margin reaching 40.3%, an increase of 6.9 percentage points versus H1 2024.